On the antiatherogenic effects of vitamin E: the search for the Holy Grail
In a recent edition of Vascular Health and Risk Management, Kirmizis and Chatzidimitriou have published a review article, “Antiatherogenic effects of vitamin E: the search for the Holy Grail”.
Beside a general evaluation of the literature on vitamin E and CVD prevention, the authors pointed out the possibility that vitamin E therapy may have particular efficacy in kidney patients. In this sense, they may represent an elective population with high susceptibility to such a secondary prevention effect, that was not identified in other cardiovascular (CVD) patient populations studied in the largest randomized controlled trials.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]